MAPK3 and Alzheimer disease: Thus, [Ca2+]i which is a known regulator of mitogen-activated protein kinase (MAPK) signalling [30], may thus mechanistically may underlie the elevated extracellular signal-regulated kinase (ERK1/2) activity observed in preclinical AD models as well as patients [31, 32].